A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer

Peritoneal Cancer ◽

Randomized Phase Ii ◽

Dose Dense

ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps5611 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS5611-TPS5611 ◽

Cited By ~ 2

Author(s):

Jane Hook ◽

Sally Patricia Stenning ◽

James Brenton ◽

Stan B Kaye ◽

Iain A. McNeish ◽

...

Keyword(s):

Randomized Trial ◽

Fallopian Tube ◽

Weekly Paclitaxel ◽

Newly Diagnosed ◽

Peritoneal Cancer ◽

Weekly Treatment ◽

Dose Dense

NRG/GOG 186K: A randomized phase II study of NCI-supplied cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer—Final results

Gynecologic Oncology ◽

10.1016/j.ygyno.2016.04.533 ◽

2016 ◽

Vol 141 ◽

pp. 207 ◽

Cited By ~ 2

Author(s):

U.A. Matulonis ◽

M. Sill ◽

P.H. Thaker ◽

J.W. Carlson ◽

C.J. Darus ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Weekly Paclitaxel ◽

Peritoneal Cancer ◽

A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.12.008 ◽

2019 ◽

Vol 152 (3) ◽

pp. 548-553 ◽

Cited By ~ 4

Author(s):

Ursula A. Matulonis ◽

Michael W. Sill ◽

Vicky Makker ◽

David G. Mutch ◽

Jay W. Carlson ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

Gynecologic Oncology ◽

10.1016/s0090-8258(21)00753-8 ◽

2021 ◽

Vol 162 ◽

pp. S58

Author(s):

Dana Roque ◽

Eric Siegel ◽

Natalia Buza ◽

Stefania Bellone ◽

Dan-Arin Silasi ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Trial ◽

Peritoneal Cancer ◽

Platinum Resistant ◽

Multicenter randomized Phase II study of AZD1775 plus chemotherapy versus chemotherapy alone in patients with platinum-resistant TP53-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps5608 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS5608-TPS5608 ◽

Cited By ~ 1

Author(s):

Kathleen N. Moore ◽

D. Scott McMeekin ◽

Erika Paige Hamilton ◽

Donald K Strickland ◽

Suzanne Fields Jones ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Peritoneal Cancer ◽

Platinum Resistant ◽

GOG 186H: A randomized phase II evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin) in the treatment of recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2016.04.042 ◽

2016 ◽

Vol 141 ◽

pp. 6-7 ◽

Cited By ~ 2

Author(s):

D.E. Cohn ◽

M. Sill ◽

J.L. Walker ◽

D.M. O'Malley ◽

C.I. Nagel ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Weekly Paclitaxel ◽

Peritoneal Cancer ◽

A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5546 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5546-5546 ◽

Cited By ~ 3

Author(s):

William P. Tew ◽

Michael Sill ◽

D. Scott McMeekin ◽

Angeles Alvarez Secord ◽

Albert J. Bonebrake ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Trial ◽

Peritoneal Cancer ◽

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70363-2 ◽

2013 ◽

Vol 14 (10) ◽

pp. 1020-1026 ◽

Cited By ~ 264

Author(s):

Noriyuki Katsumata ◽

Makoto Yasuda ◽

Seiji Isonishi ◽

Fumiaki Takahashi ◽

Hirofumi Michimae ◽

...

Keyword(s):

Fallopian Tube ◽

Long Term Results ◽

Open Label ◽

Peritoneal Cancer ◽

Open Label Trial ◽

Dose Dense ◽

Randomised Controlled

A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Annals of Oncology ◽

10.1093/annonc/mdx372.061 ◽

2017 ◽

Vol 28 ◽

pp. v352-v353

Author(s):

K.N. Moore ◽

K.A. Cadoo ◽

S. Chambers ◽

S. Ghamande ◽

G. Konecny ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Multicentre Phase ◽

Peritoneal Cancer ◽

Platinum Resistant

A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.09.048 ◽

2020 ◽

Vol 159 (3) ◽

pp. 692-698

Author(s):

M.R. Hall ◽

H.-M. Dehbi ◽

S. Banerjee ◽

R. Lord ◽

A. Clamp ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Low Dose ◽

Controlled Trial ◽

Peritoneal Cancer ◽

Metronomic Cyclophosphamide